Sub4Sub network gives free YouTube subscribers
Get Free YouTube Subscribers, Views and Likes

Adjuvant Pembrolizumab and Survival in Renal-Cell Carcinoma | NEJM

Follow
NEJM Group

Adjuvant pembrolizumab was approved for patients with renalcell carcinoma on the basis of improvements in diseasefree survival observed in the KEYNOTE564 trial. Data on overall survival are needed.

Research findings are summarized in a Quick Take video.

To see the full article, follow this link: https://nej.md/3TVLuKz

#oncology #cancerresearch #clinicaltrials #medicalresearch #nejm

posted by bionestor6j